Lumen Bioscience, Inc.
Lumen Bioscience is dedicated to unlocking the full potential of biologic drugs by transforming their development, cost, and accessibility. Utilizing patented technology, Lumen aims to develop biologic drugs faster, safer, and more effectively than traditional methods, addressing diseases that have been neglected by conventional drug-making tools.
Industries
Nr. of Employees
medium (51-250)
Lumen Bioscience, Inc. is currently seeking investment
Lumen Bioscience, Inc. is seeking a investment in the range of
Awards
Ultra-rapid, low-cost neutralizing antibody therapeutic for COVID-19
Funding (ceiling)
$9,876,609
Award Year
2020
Lysin-based Preventative for Antibiotic-Resistant Combat Wound Infections
Funding (ceiling)
$5,022,383
Award Year
2022
Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease
Oral Immunotherapy For The Prevention Of Bacterial Diarrheal Disease
Funding (ceiling)
$7,953,208
Award Year
2022
Patents
Thermostable phycobiliproteins produced from recombinant arthrospira
2025-03-18 • US-12252513-B2
View DetailsMicroorganisms with broadened light absorption capability and increased photosynthetic activity
2020-09-29 • US-10787488-B2
View Details
Thermostable phycobiliproteins produced from recombinant arthrospira
2025-03-18 • US-12252513-B2
View DetailsMicroorganisms with broadened light absorption capability and increased photosynthetic activity
2020-09-29 • US-10787488-B2
View DetailsProducts
Oral biologic cocktail for Clostridioides difficile (clinical candidate)
Capsule-formulated multi-component biologic cocktail intended to be administered alongside standard-of-care antibiotics to improve initial clinical cure and reduce recurrence of C. difficile infection; demonstrated safety and preliminary efficacy in a sentinel clinical cohort.
Needle-free intranasal recombinant vaccine for malaria (preclinical)
Preclinical intranasal vaccine based on recombinant antigen expressed in a photosynthetic microbe and formulated for needle-free administration; demonstrated sterile protection in mouse pre-erythrocytic malaria models.
Oral biologic cocktail candidates for inflammatory bowel disease and other GI indications (preclinical)
Preclinical programs developing orally delivered multi-protein cocktails targeting Crohn’s disease, ulcerative colitis, gastroenteritis and other gastrointestinal conditions.
Oral biologic cocktail for Clostridioides difficile (clinical candidate)
Capsule-formulated multi-component biologic cocktail intended to be administered alongside standard-of-care antibiotics to improve initial clinical cure and reduce recurrence of C. difficile infection; demonstrated safety and preliminary efficacy in a sentinel clinical cohort.
Needle-free intranasal recombinant vaccine for malaria (preclinical)
Preclinical intranasal vaccine based on recombinant antigen expressed in a photosynthetic microbe and formulated for needle-free administration; demonstrated sterile protection in mouse pre-erythrocytic malaria models.
Oral biologic cocktail candidates for inflammatory bowel disease and other GI indications (preclinical)
Preclinical programs developing orally delivered multi-protein cocktails targeting Crohn’s disease, ulcerative colitis, gastroenteritis and other gastrointestinal conditions.
Expertise Areas
- Oral biologic development
- Mucosal vaccine and therapeutic development (oral/intranasal)
- Photosynthetic microbe bioprocessing
- Combination antibody therapeutics
Key Technologies
- Photosynthetic microbe expression system (cyanobacterium-based)
- Chromosomal gene integration for recombinant protein expression
- Spray-drying whole-biomass formulation
- Oral capsule/tablet formulation for biologics
Featured In Technology Showcase
Ultra-Rapid, Low-Cost Neutralizing Antibody Therapeutic for COVID-19
COVID-19 is a significant force readiness issue for the United States military. In response, Lumen Bioscience has started developing and testing a low-cost, orally delivered cocktail of antibodies against SARS-CoV-2 (the virus that causes COVID-19) to prevent and treat infection of the gastrointestinal tract. A gastrointestinal-targeted therapy could reduce overall viral burden, inhibit disease progression, accelerate viral clearance, and block significant transmission routes.
News & Updates
Recognition of award winners at the MTEC Membership Meeting.
Podcast discussing innovation challenges in biotech with Lumen's Brian Finrow.
Article detailing Lumen's advancements in using spirulina for biologic drug production.
Discussion on simplifying drug development processes.
Recognition of award winners at the MTEC Membership Meeting.
Podcast discussing innovation challenges in biotech with Lumen's Brian Finrow.
Article detailing Lumen's advancements in using spirulina for biologic drug production.
Discussion on simplifying drug development processes.